| Literature DB >> 35538571 |
Mirhasan Rahimli1, Cora Wex2, Felix Wiesmueller3, Frederike Weber2, Maximilian Dölling2, Alexander Rose2, Sara Al-Madhi2, Mihailo Andric2, Roland Croner2, Aristotelis Perrakis2.
Abstract
BACKGROUND: The COVID-19 pandemic caused a global health crisis in 2020. This pandemic also had a negative impact on standard procedures in general surgery. Surgeons were challenged to find the best treatment plans for patients with acute cholecystitis. The aim of this study is to investigate the impact of the COVID-19 pandemic on the outcomes of laparoscopic cholecystectomies performed in a tertiary care hospital in Germany. PATIENTS AND METHODS: We examined perioperative outcomes of patients who underwent laparoscopic cholecystectomy during the pandemic from March 22, 2020 (first national lockdown in Germany) to December 31, 2020. We then compared these to perioperative outcomes from the same time frame of the previous year.Entities:
Keywords: COVID-19; Cholecystectomy; Cholecystitis; Hepatobiliary surgery; Laparoscopic surgery; Pandemic
Mesh:
Year: 2022 PMID: 35538571 PMCID: PMC9087165 DOI: 10.1186/s12893-022-01621-z
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Patient characteristics and preoperative parameters
| Control group n (%) or mean (SD) | Pandemic group n (%) or mean (SD) | p-value | Total | |
|---|---|---|---|---|
| Total (n) | 82 (45.1) | 100 (54.9) | 182 (100.0) | |
| Sex | ||||
| | 32 (39.0) | 46 (46.0) | 0.344 | 78 (42.9) |
| | 50 (61.0) | 54 (54.0) | 104 (57.1) | |
| Age; years | 54.4 (19.0) | 55.9 (17.5) | 0.606 | 55.2 (18.2) |
| Number of elderly patients; > 65 yo | 28 (34.1) | 34 (34.0) | 0.983 | 62 (34.1) |
| BMI; kg/m2 | 29.7 (6.3) | 29.9 (6.9) | 0.971 | 29.8 (6.6) |
| ASA | ||||
| 1 | 4 (4.9) | 8 (8.0) | 0.637 | 12 (6.6) |
| 2 | 56 (68.3) | 63 (63.0) | 119 (65.4) | |
| 3 | 22 (26.8) | 28 (28.0) | 50 (27.5) | |
| 4 | 0 (0.0) | 1 (1.0) | 1 (0.5) | |
| Previous abdominal surgery | 26 (31.7) | 25 (25.0) | 0.316 | 51 (28.0) |
| Cholecystitis | 20 (24.4) | 37 (37.0) | 0.068 | 57 (31.3) |
| Gangrenous cholecystitis | 2 (2.4) | 7 (7.0) | 0.188 | 9 (4.9) |
| Biliary pancreatitis | 12 (14.6) | 19 (19.0) | 0.436 | 31 (17.0) |
| Choledocholithiasis | 27 (32.9) | 26 (26.0) | 0.306 | 53 (29.1) |
| ERCP with SE | 18 (22.0) | 18 (18.0) | 0.506 | 36 (19.8) |
| ERCP with BSI | 1 (1.2) | 4 (4.0) | 0.380 | 5 (2.7) |
ASA American Society of Anesthesiologists, BMI body mass index, BSI biliary stent implantation, ERCP endoscopic retrograde cholangiopancreatography, SD standard deviation, SE stone extraction, yo years old
Intra- and postoperative outcomes
| Control group n (%) or mean (SD) | Pandemic group n (%) or mean (SD) | p-value | Total | |
|---|---|---|---|---|
| Total (n) | 82 (45.1) | 100 (54.9) | 182 (100.0) | |
| Early cholecystectomy | 19 (23.2) | 36 (36.0) | 0.061 | 55 (30.2) |
| Operation time; min | 94.5 (37.0) | 90.0 (40.2) | 0.266 | 92.0 (38.8) |
| IBL; ml | 57.5 (73.9) | 79.2 (124.1) | 0.740 | 69.4 (104.8) |
| LOS; days | 4.2 (2.4) | 4.2 (3.0) | 0.337 | 4.2 (2.8) |
| Overall morbidity | 10 (12.2) | 8 (8.0) | 0.346 | 18 (9.9) |
| Severe complications (Clavien-Dindo > II) | 2 (2.4) | 5 (5.0) | 0.460 | 7 (3.8) |
| Surgical revision | 0 (0.0) | 1 (1.0) | 1.000 | 1 (0.5) |
| 30-day readmission | 1 (1.2) | 2 (2.0) | 1.000 | 3 (1.6) |
| 30-day mortality | 0 (0.0) | 1 (1.0) | 1.000 | 1 (0.5) |
IBL intraoperative blood loss, LOS length of stay, SD standard deviation
Postoperative complications
| Complication | Number | Management | Clavien-Dindo Classification |
|---|---|---|---|
| Allergic reaction | 1 | conservative | II |
| Postoperative delirium | 1 | conservative | II |
| Postoperative renal failure | 1 | conservative | II |
| Wound/abdominal wall hematoma | 3 | conservative, cooling/compression | I |
| 1 | conservative, blood transfusion | II | |
| Bile leakage | 2 | conservative, spontaneous regression | I |
| Gallbladder bed hematoma | 2 | conservative, blood transfusion | II |
| Gallbladder bed biloma | 1 | interventional, CT-guided percutaneous drainage | IIIa |
| Residual stones in bile duct | 2 | ERCP with SE | IIIb |
| Cystic duct stump leak | 1 | ERCP with BSI | IIIb |
| Iatrogenic bile duct injury | 1 | revision, biliodigestive anastomosis | IIIb |
| Wound infection with abdominal wall abscess | 1 | surgical wound revision | IIIb |
| Multi-organ failure/death | 1 | V |
BSI biliary stent implantation, CT computed tomography, ERCP endoscopic retrograde cholangiopancreatography, SE stone extraction
Perioperative outcomes in elderly patients (> 65 years old)
| Control group n (%) or mean (SD) | Pandemic group n (%) or mean (SD) | p-value | Total | |
|---|---|---|---|---|
| Total (n) | 28 (45.2) | 34 (54.8) | 62 (100.0) | |
| Cholecystitis | 5 (17.9) | 20 (58.8) | 25 (40.3) | |
| Gangrenous cholecystitis | 0 (0.0) | 7 (20.6) | 7 (11.3) | |
| Biliary pancreatitis | 6 (21.4) | 9 (26.5) | 0.645 | 15 (24.2) |
| Early cholecystectomy | 5 (17.9) | 20 (58.8) | 25 (40.3) | |
| Operation time; min | 103.0 (33.2) | 99.6 (38.6) | 0.534 | 101.1 (36.0) |
| IBL; ml | 65.7 (69.3) | 144.7 (167.2) | 0.125 | 109.0 (137.2) |
| LOS; days | 5.1 (3.7) | 6.1 (4.4) | 0.174 | 5.7 (4.1) |
| Overall morbidity | 9 (32.1) | 7 (20.6) | 0.301 | 16 (25.8) |
| 30-day mortality | 0 (0.0) | 1 (2.9) | 1.000 | 1 (1.6) |
IBL intraoperative blood loss, LOS length of stay, SD standard deviation
Significant values (p < 0.05) marked in bold
Perioperative outcomes in converted cases
| Control group n (%) or mean (SD) | Pandemic group n (%) or mean (SD) | p value | Total | |
|---|---|---|---|---|
| Total (n) | 10 (50.0) | 10 (50.0) | 20 (100.0) | |
| Sex | ||||
| | 8 (80.0) | 9 (90.0) | 1.000 | 17 (85.0) |
| | 2 (20.0) | 1 (10.0) | 3 (15.0) | |
| Age; years | 69.9 (9.4) | 67.3 (7.3) | 0.684 | 68.6 (8.3) |
| Cholecystitis | 10 (100.0) | 10 (100.0) | 20 (100.0) | |
| Gangrenous cholecystitis | 4 (40.0) | 3 (30.0) | 1.000 | 7 (35.0) |
| Biliary pancreatitis | 1 (10.0) | 1 (10.0) | 1.000 | 2 (10.0) |
| Early cholecystectomy | 8 (80.0) | 6 (60.0) | 0.628 | 14 (70.0) |
| Operation time; min | 138.9 (54.5) | 152.2 (64.4) | 0.912 | 145.6 (58.5) |
| IBL; ml | 333.3 (510.5) | 235.0 (122.6) | 0.356 | 281.6 (354.8) |
| LOS; days | 11.5 (9.2) | 7.9 (2.5) | 0.739 | 9.7 (6.8) |
| Overall morbidity | 2 (20.0) | 3 (30.0) | 1.000 | 5 (25.0) |
| 30-day mortality | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Wound infection (CD 1) | 1 (10.0) | 1 (10.0) | 0.547 | 2 (10.0) |
| Wound hematoma (CD 1) | 0 (0.0) | 1 (10.0) | 1 (5.0) | |
| Postoperative pneumonia (CD 2) | 0 (0.0) | 1 (10.0) | 1 (5.0) | |
| Iatrogenic bile duct injury (CD IIIb) | 1 (10.0) | 0 (0.0) | 1 (5.0) | |
| Total | 2 (20.0) | 3 (30.0) | 5 (25.0) | |
| Massive inflammatory adhesions | 4 (40.0) | 6 (60.0) | 0.315 | 10 (50.0) |
| Dissection difficulties | 3 (30.0) | 4 (40.0) | 7 (35.0) | |
| Bleeding | 2 (20.0) | 0 (0.0) | 2 (10.0) | |
| Ventilation difficulties | 1 (10.0) | 0 (0.0) | 1 (5.0) | |
| Total | 10 (100.0) | 10 (100.0) | 20 (100.0) | |
CD Clavien-Dindo, IBL intraoperative blood loss, LOS length of stay, SD standard deviation